{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T13:12:29Z","timestamp":1704114749923},"reference-count":30,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,2,1]]},"abstract":"<jats:p>Human immunodeficiency virus (HIV) lipodystrophy (LIPO) is characterized by increased visceral adiposity, peripheral fat atrophy, dyslipidemia, and insulin resistance. GH concentrations are known to vary inversely with excess weight and body fat but have not been investigated in HIV lipodystrophy. Twenty-one subjects with HIV LIPO, 20 HIV-infected nonlipodystrophy subjects (NONLIPO), and 20 control (C) subjects were prospectively recruited for this study and compared.<\/jats:p>\n               <jats:p>Subjects in the three groups were all male, age-matched [median, 47 yr old (interquartile range, 37\u201350) LIPO; 41 (37\u201344) NONLIPO; and 43 (37\u201349) C], and body mass index-matched [median, 24.3 kg\/m2 (interquartile range, 22.2\u201326.6) LIPO; 24.4 (23.3\u201325.9) NONLIPO; and 24.8 (22.7\u201326.1) C] (P&amp;gt; 0.05 for all comparisons). Visceral abdominal fat [16,124 mm2 (11,246\u201319,790) LIPO; 7,559 (5,134\u201311,201) NONLIPO; and 8,803 (6,165\u201311,623) C; P &amp;lt; 0.01 LIPO vs. NONLIPO and LIPO vs. C] and the ratio of visceral abdominal fat to sc abdominal fat [1.37 (0.71\u20132.44) LIPO vs. 0.57 (0.47\u20130.78) NONLIPO vs. 0.55 (0.41\u20130.71) C, P &amp;lt; 0.01 LIPO vs. NONLIPO and LIPO vs. C] were significantly increased in the LIPO subjects but were not significantly different between NONLIPO and C. The mean overnight GH concentration, determined from frequent sampling every 20 min (from 2000 h to 0800 h) was decreased in the LIPO subjects [0.38 \u03bcg\/L (0.13\u20130.67) LIPO vs. 0.96 (0.53\u20131.30) NONLIPO vs. 0.81 (0.49\u20131.03) C, P &amp;lt; 0.05 LIPO vs. NONLIPO and LIPO vs. C] and not significantly different between NONLIPO and C. Pulse analysis demonstrated decreased baseline GH [0.08 \u03bcg\/L (0.06\u20130.21) LIPO vs. 0.19 (0.10\u20130.32) NONLIPO vs. 0.17 (0.12\u20130.57) C, P &amp;lt; 0.05 LIPO vs. NONLIPO and LIPO vs. C] and GH peak amplitude [1.06\u03bc g\/L (0.46\u20131.94) LIPO vs. 2.47 (1.22\u20133.43) NONLIPO and 2.27 (1.36\u20134.25) C, P &amp;lt; 0.05 LIPO vs. NONLIPO and LIPO vs. C] in the LIPO subjects but no significant difference in pulse frequency. No significant differences were observed between NONLIPO and C for any GH parameter. Insulin-like growth factor-I was not different between the groups. Total body fat (r = \u22120.40, P = 0.01) and visceral fat (r = \u22120.58, P = 0.0001) correlated inversely with mean overnight GH concentrations in the HIV-infected patients. In a multivariate regression model, controlling for age, body mass index, body fat, and visceral fat, only visceral fat was a significant predictor of mean GH concentrations (P = 0.0036, r2 for model = 0.40).<\/jats:p>\n               <jats:p>These data demonstrate normal GH pulse frequency and insulin-like growth factor-I concentrations but reduced mean GH concentrations, basal GH concentrations, and GH pulse amplitude in patients with HIV lipodystrophy. Increased visceral adiposity is the strongest predictor of reduced GH concentrations in HIV lipodystrophy. Further studies are necessary to determine the clinical significance of reduced GH in patients with HIV lipodystrophy.<\/jats:p>","DOI":"10.1210\/jcem.86.2.7175","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T17:06:55Z","timestamp":1389200815000},"page":"504-510","source":"Crossref","is-referenced-by-count":9,"title":["Assessment of Growth Hormone Dynamics in Human Immunodeficiency Virus-Related Lipodystrophy1"],"prefix":"10.1210","volume":"86","author":[{"given":"Petra","family":"Rietschel","sequence":"first","affiliation":[{"name":"Neuroendocrine Unit (P.R., C.H., C.C., T.S., S.G.), Boston, Massachusetts 02114"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"Hadigan","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit (P.R., C.H., C.C., T.S., S.G.), Boston, Massachusetts 02114"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"Corcoran","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit (P.R., C.H., C.C., T.S., S.G.), Boston, Massachusetts 02114"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takara","family":"Stanley","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit (P.R., C.H., C.C., T.S., S.G.), Boston, Massachusetts 02114"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Neubauer","sequence":"additional","affiliation":[{"name":"the General Clinical Research Center (G.N.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Gertner","sequence":"additional","affiliation":[{"name":"Serono Laboratories, Inc. (J.G.), Norwell, Massachusetts 02061"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Grinspoon","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit (P.R., C.H., C.C., T.S., S.G.), Boston, Massachusetts 02114"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071617384640900_R1","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving protease inhibitor therapy","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS."},{"key":"2020071617384640900_R2"},{"key":"2020071617384640900_R3","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor associated lipodystrophy, hyperlipidemia, and diabetes mellitus: a cohort study","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet."},{"key":"2020071617384640900_R4","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(97)11518-5","article-title":"Visceral abdominal-fat accumulation associated with use of indinavir","volume":"351","author":"Miller","year":"1998","journal-title":"Lancet."},{"key":"2020071617384640900_R5","first-page":"225","article-title":"Diabetes, insulin resistance and dyslipidemia in lipodystrophic HIV-infected patient on highly active antiretroviral therapy (HAART)","volume":"25","author":"Vigouroux","year":"1999","journal-title":"Diabete Metab."},{"key":"2020071617384640900_R6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00042560-200001010-00005","article-title":"Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection","volume":"23","author":"Mulligan","year":"2000","journal-title":"J Acquir Immune Defic Syndr."},{"key":"2020071617384640900_R7","doi-asserted-by":"crossref","first-page":"F25","DOI":"10.1097\/00002030-200002180-00001","article-title":"A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome","volume":"14","author":"Carr","year":"2000","journal-title":"AIDS."},{"key":"2020071617384640900_R8","first-page":"3209","article-title":"Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay","volume":"80","author":"Veldhuis","year":"1995","journal-title":"J Clin Endocrinol Metab."},{"key":"2020071617384640900_R9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1210\/jcem-72-1-51","article-title":"Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man","volume":"72","author":"Veldhuis","year":"1991","journal-title":"J Clin Endocrinol Metab."},{"key":"2020071617384640900_R10","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/0026-0495(92)90220-5","article-title":"Arginine potentiates but does not restore the blunted growth hormone response to growth-hormone releasing hormone in obesity","volume":"41","author":"Ghigo","year":"1992","journal-title":"Metabolism."},{"key":"2020071617384640900_R11","first-page":"84","article-title":"Assessment of growth hormone (GH) secretion in men with adult-onset GH deficiency compared with that in normal men \u2014 a clinical research center study","volume":"81","author":"Baum","year":"1996","journal-title":"J Clin Endocrinol Metab."},{"key":"2020071617384640900_R12","first-page":"2","article-title":"Height and weight tables","volume":"64","year":"1983","journal-title":"Stat Bull Metrop Insur Co."},{"key":"2020071617384640900_R13","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/ajcn\/51.6.1106","article-title":"Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition","volume":"51","author":"Mazess","year":"1990","journal-title":"Am J Clin Nutr."},{"key":"2020071617384640900_R14","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/ajcn\/36.1.172","article-title":"Assessment of abdominal fat content by computed tomography","volume":"36","author":"Borkan","year":"1982","journal-title":"Am J Clin Nutr."},{"key":"2020071617384640900_R15","first-page":"718","article-title":"Case records of the Massachusetts General Hospital","volume":"327","author":"Jordan","year":"1992","journal-title":"Weekly clinicopathological exercises. Normal reference laboratory values. N Engl J Med."},{"key":"2020071617384640900_R16"},{"key":"2020071617384640900_R17","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.CIR.100.7.700","article-title":"Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors","volume":"100","author":"Periard","year":"1999","journal-title":"Circulation."},{"key":"2020071617384640900_R18","doi-asserted-by":"crossref","first-page":"F167","DOI":"10.1097\/00002030-199815000-00001","article-title":"Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients","volume":"12","author":"Walli","year":"1998","journal-title":"AIDS."},{"key":"2020071617384640900_R19","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/00002030-199909100-00009","article-title":"A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy","volume":"13","author":"Saint-Marc","year":"1999","journal-title":"AIDS."},{"key":"2020071617384640900_R20","first-page":"4051","article-title":"Loss of lean body mass and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting","volume":"81","author":"Grinspoon","year":"1996","journal-title":"J Clin Endocrinol Metab."},{"key":"2020071617384640900_R21","first-page":"4028","article-title":"Circadian growth hormone secretion in asymptomatic human immune deficiency virus infection and acquired immunodeficiency syndrome","volume":"81","author":"Heijligenberg","year":"1996","journal-title":"J Clin Endocrinol Metab."},{"key":"2020071617384640900_R22","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/0026-0495(93)90251-I","article-title":"Serum growth hormone responses to growth-hormone releasing hormone in non-obese and obese adults with hypopituitarism","volume":"42","author":"Bing-You","year":"1993","journal-title":"Metabolism."},{"key":"2020071617384640900_R23","first-page":"83","article-title":"Low concentrations of insulin-like growth factor-I in abdominal obesity","volume":"17","author":"Marin","year":"1993","journal-title":"Int J Obes."},{"key":"2020071617384640900_R24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/0026-0495(92)90198-J","article-title":"The distal axis of growth hormone (GH) in nutritional disorders: GH-binding protein, insulin-like growth factor-I (IGF-I), and IGF-I receptors in obesity and anorexia nervosa","volume":"41","author":"Hochberg","year":"1992","journal-title":"Metabolism."},{"key":"2020071617384640900_R25","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jcem-70-5-1361","article-title":"Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects","volume":"70","author":"Cordido","year":"1990","journal-title":"J Clin Endocrinol Metab."},{"key":"2020071617384640900_R26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1210\/jcem-68-2-290","article-title":"Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity","volume":"68","author":"Cordido","year":"1989","journal-title":"J Clin Endocrinol Metab."},{"key":"2020071617384640900_R27","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0026-0495(89)90099-1","article-title":"Effect of cholinergic enhancement by pyridostigmine on growth hormone secretion in obese adults and children","volume":"38","author":"Ghigo","year":"1989","journal-title":"Metabolism."},{"key":"2020071617384640900_R28","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1159\/000125262","article-title":"In vitro and in vivo growth hormone responsiveness to growth hormone-releasing factor in male and female Zucker rats","volume":"50","author":"Renier","year":"1989","journal-title":"Neuroendocrinology."},{"key":"2020071617384640900_R29","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1210\/endo-127-6-3087","article-title":"Mechanisms of impaired growth hormone secretion in genetically obese Zucker rats; roles of growth hormone- releasing factor and somatostatin","volume":"127","author":"Tannenbaum","year":"1990","journal-title":"Endocrinology."},{"key":"2020071617384640900_R30","first-page":"727","article-title":"Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism and reduces diastolic blood pressure","volume":"82","author":"Johannson","year":"1997","journal-title":"J Clin Endocrinol Metab."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/86\/2\/504\/9129891\/jcem0504.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/86\/2\/504\/9129891\/jcem0504.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:34:55Z","timestamp":1594956895000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/86\/2\/504\/2840846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2,1]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jcem.86.2.7175","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,2,1]]}}}